Skip to main navigation

Skip links

  • Skip to content
  • Skip to footer

Akari TX

Main navigation

Menu
    • HOME
    • ABOUT
      • Close
      • MANAGEMENT
      • BOARD OF DIRECTORS
    • COVID-19
    • LEAD INDICATIONS
      • Close
      • OVERVIEW
      • BP-PIVOTAL
      • TMA-HSCT – PIVOTAL
      • AKC PHASE I/II
        • Close
        • CLINICAL DATASET
      • CLINICAL DATASET
      • PRECLINICAL PROGRAMS
        • Close
        • NOMACOPAN LA
        • VOTUCALIS
        • OTHER INDICATIONS
    • THE SCIENCE
      • Close
      • OVERVIEW
      • MODE OF ACTION
      • TARGET PATHWAYS
        • Close
        • C5 (COMPLEMENT SYSTEM)
        • LTB4 (LEUKOTRINE SYSTEM)
      • MOLECULES
        • Close
        • NOMACOPAN
        • OTHER NOMACOPAN-BASED MOLECULES
        • VOTUCALIS
    • INVESTOR RELATIONS
      • Close
      • OVERVIEW
      • GENERAL MEETING OF SHAREHOLDERS
      • FINANCIAL INFORMATION
        • Close
        • SEC FILINGS
        • ANNUAL REPORTS
      • NEWS & EVENTS
        • Close
        • PRESS RELEASES
        • EVENTS
        • PRESENTATIONS
      • STOCK INFORMATION
        • Close
        • STOCK QUOTE & CHART
        • HISTORIC PRICE LOOKUP
        • INVESTMENT CALCULATOR
      • CORPORATE GOVERNANCE
        • Close
        • GOVERNANCE OVERVIEW
        • BOARD OF DIRECTORS
        • MANAGEMENT
        • COMMITTEE COMPOSITION
      • INVESTOR RESOURCES
        • Close
        • INVESTOR FAQS
        • EMAIL ALERTS
    • PRESS
      • Close
      • PRESS RELEASES
      • PUBLICATIONS
    • CONTACT US

Financial Information

Financial Information

  • Print Page
  • Email Alerts
  • RSS Feeds
  • Contact Us

Footer

Akari TX

LONDON

75/76 Wimpole Street London W1G 9RT UK

T: +44 (0)20.8004.0261
E: info@Akaritx.com

NEW YORK

135 W 41st Street. 5th Floor New York, NY, 10036

T: 929.274.7510
F: 646.843.9352
E: info@Akaritx.com

Copyright © 2021 Akari Therapeutics Plc. All rights reserved.